hydroxychloroquine / Generic mfg. - LARVOL DELTA

Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications (ASH 2025) - "For lupus manifestations, 15 patients received hydroxychloroquine (HCQ) alone and 4 achieved compplete remission (CR); 12 patients received HCQ in combination with oral corticosteroids and 6 achieved CR. Seven patients with active LE received specific treatment for MDS/CMML: 1 with MDS-IB2 received allo-SCT, achieving hematology and LE CR.; 1 with AML received azacytidine (AZA) and venetoclax, achieving hematological and LE CR...Improvement of systemic manifestations following hematologic treatment suggests that clinical features may be clone-dependent. In patients with atypical or treatment-resistant lupus, especially in older adults, men, or those with chilblain CLE, cytopenia, a myeloid neoplasm should be systematically considered, and clone-directed hematologic therapy may be considered."

Chronic Myelomonocytic Leukemia • Cutaneous Lupus Erythematosus • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Lupus • Lupus Nephritis • Myelodysplastic Syndrome • Nephrology • Systemic Lupus Erythematosus • ASXL1 • KRAS • NRAS • SRSF2 • TET2

From unexplained cytopenias to clonality: Diagnosing T-cell large granular lymphocytic leukemia in rheumatoid arthritis via integrated molecular profiling (ASH 2025) - "We present a diagnostically complex case of T-LGL leukemia in the setting of longstanding RA, initially misattributed to hydroxychloroquine-induced cytopenia...The patient was started on prednisone 60 mg daily for 7 days, leading to a prompt rise in ANC to 1.4 × 10⁹/L, followed by tapering...Plans were made to initiate low-dose methotrexate for treatment of both T-LGL and RA...In this case, the clinical suspicion for clonal lymphoproliferative disease remained high despite inconclusive flow cytometry, prompting further molecular testing that ultimately confirmed the diagnosis. An integrated diagnostic approach that includes molecular and clonality testing can help distinguish T-LGL leukemia from reactive or drug-induced cytopenias, enabling timely and targeted immunosuppressive therapy."

Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Leukopenia • Pulmonary Disease • Rheumatoid Arthritis • Rheumatology • T-Cell Large Granular Lymphocyte Leukemia • CD8 • STAT3 • TNFAIP3 • TRG

Immunosuppressant use and adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective cohort study in Korea. (PubMed, Rheumatology (Oxford)) - "Continuity of hydroxychloroquine use from preconception through pregnancy reduces preterm birth risk in SLE. Conversely, early exposure to teratogenic immunosuppressants heightens the risk of spontaneous abortion. These findings underscore the importance of preconception medication planning in women with SLE."

Adverse events • Journal • Retrospective data • Gynecology • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Multisystem flare of systemic lupus erythematosus presenting with severe warm autoimmune hemolytic anemia: A diagnostic and transfusion challenge (ASH 2025) - "Case Presentation: A 43-year-old woman with established SLE (diagnosed in 2016), previously treated with hydroxychloroquine and methotrexate, presented with fatigue, jaundice, dark urine, and right upper quadrant discomfort...The patient was premedicated with IV methylprednisolone and diphenhydramine and transfused with two units of the least incompatible RBCs...She received methylprednisolone 1 g IV daily for three days, followed by oral prednisone (1 mg/kg/day)... Severe wAIHA in SLE demands rapid diagnosis, interdepartmental collaboration, and flexibility in transfusion strategies. The least incompatible RBC transfusion, combined with immunosuppressive therapy, can be lifesaving. Comprehensive evaluation of systemic involvement is essential in such complex flares."

Anemia • Autoimmune Hemolytic Anemia • Autoimmune Hepatitis • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Solid Tumor • Systemic Lupus Erythematosus • Uterine Leiomyoma

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure. (ASH 2025) - "Treatment included prednisone in 284 (92.5%),mycophenolate in 145 (47.2%), azathioprine (AZA) in 144 (46.9%), a calcineurin inhibitor in 54 (17.6%),hydroxychloroquine in 51 (16.6%), extracorporeal photopheresis in 20 (6.5%), and rituximab in 10 (3.3%).A propensity score was calculated from the following unbalanced clinical factors: age (≥60 vs. <60), GvHDseverity (severe vs. mild/moderate), HCT-CI score (≥3 vs. <3), and treatment line (≥4th vs. <4th). The BEL group showed 72.0% [55.0–83.4] 12 months' FFS rate vs25.3% [10.6–43.1] for BAT (p<0.001), whereas 12 months' OS rates were 92.1% [77.3–97.4] and 88.4%[60.8–97.0] (p=0.317), respectively.Both univariate (UVA) and multivariate analysis (MVA) (BEL vs. BAT, HCT-CI ≥3, severe cGvHD, age ≥ 60,and previous acute GvHD) for FFS confirmed BEL superiority over BAT (hazard ratio (HR) 0.288 [0.155–0.535], p<0.001; no differences for the other factors). For OS, UVA showed that BEL had a trend for ahigher OS..."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor (ASH 2025) - "We sought to definethis cohort of responders to a second IL-6 inhibitor by comparing them to patients refractory to bothsiltuximab and tocilizumab.MethodsWe utilized two registries: ACCELERATE, the largest international registry of iMCD patients, that leveragesan expert panel to confirm every patient diagnosis, and Peking Union Medical College Hospital, thelargest single-center registry of Chinese iMCD patients...Six of 9 patientsreceived corticosteroids with the first IL-6 inhibitor, and 3 received other medications(hydroxychloroquine, rituximab, sirolimus, and chemotherapy)...Despite limited numbers, we observed that responders to a second IL-6inhibitor were more likely to have the IPL subtype. In a disease with few alternatives, this cohort suggestsan unexpected therapeutic benefit to trialing a second IL-6 inhibitor following an initial nonresponse."

Clinical • Fibrosis • Hematological Disorders • Immunology • Inflammation • Nephrology • Rare Diseases • Renal Disease • Thrombocytopenia • CRP

Platelet factor 4 (PF4) modulates endothelial cell antimicrobial activity to enhance bacterial clearance and improve sepsis outcomes (ASH 2025) - "A subset was then pre-treated with AMG-487(20µg/mL), Dynasore (100µM), Pitstop (30µM), heparinases (1U/mL), or hydroxychloroquine (HCQ; 50µM).Prior to exposure to E coli at a multiplicity of infection of 10 ± PF4 (25µg/mL) for 1h at 37°C... This study uncovers a critical role for plt PF4 in enhancing host defense against bloodstreaminfections by promoting EC uptake and clearance of bacteria. Beyond expanding the known functions ofPF4, our findings support a broader concept that ECs, long recognized as a passive barrier, activelycontribute to innate immune defense during systemic infection."

Infectious Disease • Inflammation • Septic Shock • CXCR3

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis (ASH 2025) - "Prescription refills in pharmacy claim records wereused to determine RUX and prednisone-equivalent CS dosing and treatment length. Line of therapy forcGVHD medications was based on claims for CS, belumosudil, abatacept, alemtuzumab, RUX, etanercept,hydroxychloroquine, ibrutinib, imatinib, interleukin-2, methotrexate, mycophenolate mofetil, pentostatin,and rituximab after cGVHD diagnosis... Patients treated with RUX for cGVHD in real-world clinical practice remained on treatmentfor a median of 8 months; 40.9% remained on RUX for 1 year and 21.3% for 2 years, suggesting long-termpersistence of safety and ongoing clinical benefit. Median time from earliest CS fill for cGVHD todiscontinuation or reduction to low-dose CS was 77 days. By the end of 1-year follow-up, 90% of patientsachieved discontinuation or reduction to low-dose CS."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • IL2

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

DP03 Psoriasiform lesions in a patient with pulmonary disease. (PubMed, Br J Dermatol) - "Treatment typically involves systemic steroids for acute disease, with steroid-sparing agents such as methotrexate or hydroxychloroquine used for long-term management. Early diagnosis and appropriate treatment are critical to managing the disease's progressive nature and avoiding complications."

Journal • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Metabolic Disorders • Mycosis Fungoides • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • Sarcoidosis

BH18 A rare case of nail sarcoidosis presenting as an ulcerated nail tumour in a Afro-Caribbean patient. (PubMed, Br J Dermatol) - "At the time of referral to dermatology, his scrotal and skeletal sarcoidosis had not been fully controlled on single-agent methotrexate 20 mg weekly, so adalimumab 40 mg fortnightly had been added with subsequent discontinuation of methotrexate after 2 months of dual therapy...Plaquenil 200 mg twice daily was added, with a marked improvement in both his cutaneous and nail sarcoid. We present this interesting case to highlight the awareness of nail sarcoid being a possible cause of a destructive nail process in this population group, with the aim of increasing awareness of nail sarcoidosis and the extent of possible systemic involvement. We highlight the usefulness of nailbed biopsy and X-ray of the hands in this case, in addition to the importance of thorough systemic evaluation and investigations where appropriate in sarcoidosis."

Journal • Dermatology • Immunology • Melanoma • Oncology • Rheumatology • Sarcoidosis • Solid Tumor

P112 A retrospective review of the oral manifestations of lupus erythematosus. (PubMed, Br J Dermatol) - "Management included topical corticosteroids in 52%, with systemic therapy (prednisolone, hydroxychloroquine, mycophenolate mofetil, mepacrine, abatacept, rituximab) added in 64%. This review of OLE, the largest series to our knowledge, demonstrates a predilection for the buccal mucosa, hard palate and lip. Specific clinical features help to differentiate oral LE from other mucosal inflammatory conditions and therefore guide optimal patient management."

Journal • Retrospective data • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Lupus

BH28 Breaking the pattern: frontal fibrosing alopecia in men, a case series. (PubMed, Br J Dermatol) - "Treatment with topical corticosteroids, lymecycline, doxycycline and hydroxychloroquine led to partial stabilization, although significant psychological distress persisted. In 2023 a genome-wide association study also identified two genes associated with male FFA, which were different from genes implicated in women. These cases highlight the potential for further research into possible environmental and genetic triggers and novel treatment approaches."

Journal • Alopecia • CNS Disorders • Dermatology • Dermatopathology • Fibrosis • Immunology • Infectious Disease • Inflammation • Lichen Planus • Novel Coronavirus Disease

BH27 When patterns blur: recognizing the overlap of alopecia areata and lichen planopilaris. (PubMed, Br J Dermatol) - "Treatments to date have included triamcinolone injections, oral hydroxychloroquine and oral minoxidil, with some symptomatic relief and clinical improvement. This case emphasizes the importance of recognizing the overlap between alopecia areata and lichen planopilaris, which are rarely documented together, as well as the necessity for a comprehensive clinical and histological evaluation in atypical presentations of hair loss. The report contributes to the limited literature on this dual diagnosis and may guide future clinical management strategies for similar cases."

Journal • Alopecia • Dermatology • Fibrosis • Immunology • Inflammation • Lichen Planus

Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data. (PubMed, Front Immunol) - "Our machine-learning models (trained and validated separately for each drug) achieved high predictive performance (tofacitinib: ROC-AUC 0.82, accuracy 80%; baricitinib: ROC-AUC 0·88, accuracy 88%), identifying key clinical factors such as total cholesterol, CRP, and specific joint swelling or tenderness for tofacitinib, and patient global assessment, joint swelling, and co-administration of hydroxychloroquine for baricitinib. Model-guided treatment selection could have improved outcomes for an additional 15% of patients by aligning each individual's predicted response with the more suitable Janus kinase inhibitor. The findings suggest that ML models can accurately predict treatment response to Janus kinase inhibitors in rheumatoid arthritis and may support personalized therapy selection to improve clinical outcomes."

Clinical data • Journal • Retrospective data • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

P048 Lenalidomide use in recalcitrant inflammatory dermatoses: a trio of successes. (PubMed, Br J Dermatol) - "A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses."

Journal • Cardiovascular • Cataract • Dental Disorders • Dermatology • Discoid Lupus Erythematosus • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Oncology • Ophthalmology • Pain • Peripheral Neuropathic Pain • Rheumatology • Stomatitis • Systemic Lupus Erythematosus • Thrombocytopenia • IL12A • IL6

CPC12 An unusual case of paraneoplastic sarcoid presenting as dactylitis. (PubMed, Br J Dermatol) - "A diagnosis of sarcoid dactylitis was made and treatment commenced with a reducing course of prednisolone 40 mg daily, along with hydroxychloroquine 200 mg twice daily...The radiological findings can therefore aid diagnosis. Our case highlights the rare initial presentation of dactylitis as a manifestation of paraneoplastic sarcoid."

Journal • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Oncology • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Thyroid Gland Carcinoma • Tuberculosis • IFNG • IL2

DP13 Keep calm and shoulder on: a lesion that can't be shrugged off. (PubMed, Br J Dermatol) - "The second cycle of adjuvant chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide) caused right-upper-limb phlebitis and lymphangitis with permanent damage to local vasculature...She was on hydroxychloroquine for long-standing rheumatoid arthritis, having previously received methotrexate and sulfasalazine...Some cases described in the literature as APL in irradiated areas are possibly the lymphatic subtype of an AVL. As there was no latency between irradiation and onset, our case is more likely APL, rather than AVL outside the field of irradiation."

Journal • Angiosarcoma • Breast Cancer • Epstein-Barr Virus Infections • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Sarcoma • Solid Tumor • CD31 • CD34 • MYC • PECAM1

BH04 Growing interest: a survey of low-dose oral minoxidil prescribing for hair loss. (PubMed, Br J Dermatol) - "For female pattern hair loss, 90% (n = 26) would prescribe LDOM as monotherapy and 66% (n = 19) would use it with spironolactone. For FFP/LPP, 79% (n = 23) would not prescribe LDOM as monotherapy, but would use it as an adjunct, most commonly with hydroxychloroquine (n = 20), followed by tetracyclines (n = 19)...Our study highlights the variation in LDOM prescribing within the UK and Ireland. It demonstrates the wide use of LDOM by dermatologists both as an adjunct and as monotherapy for a wide range of hair loss conditions."

Journal • Alopecia • Fibrosis • Immunology • Lichen Planus

PSD02 Where the sun don't shine: a rare case of genital lupus erythematosus. (PubMed, Br J Dermatol) - "In addition to hydroxychloroquine and mycophenolate mofetil, therapy directed at genital involvement with mepacrine and superpotent topical steroid under occlusion was initiated with good response. Important differentials to consider include herpes simplex, squamous cell carcinoma and sexually transmitted disease. Early diagnosis and treatment are key to avoiding scarring and disfigurement."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Dermatopathology • Discoid Lupus Erythematosus • Herpes Simplex • Immunology • Infectious Disease • Inflammatory Arthritis • Lichen Planus • Lupus • Nephrology • Oncology • Squamous Cell Carcinoma • Urology

BI17 Generalized morphoea associated with anaplastic lymphoma and Hodgkin lymphoma: a report of two cases. (PubMed, Br J Dermatol) - "Initial management included methotrexate, pulsed methylprednisolone, hydroxychloroquine and ultraviolet (UV)A1 phototherapy...She was treated with six cycles of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine chemotherapy and remains in remission...Immunosuppressive medications for morphoea were discontinued, and she had a poor response to the initial chemotherapy regimen of brentuximab, cyclophosphamide, doxorubicin and prednisolone...These cases highlight the intricate interplay between generalized morphoea and lymphoma, emphasizing the need for a tailored approach to therapy. The heightened risk of lymphoma in autoimmune conditions necessitates careful balancing of immunosuppression and oncological treatment, with a close multidisciplinary approach to optimize patient outcomes."

Journal • Acromegaly • B Cell Lymphoma • Dermatology • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Sjogren's Syndrome • Transplantation

A pivotal phase II, randomized, controlled, open-label, trial (MIZAR-003) to assess the efficacy and safety of GC101 TIL, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, for patients with advanced anti-PD-1 refractory melanoma in later-line therapy (ESMO Asia 2025) - P2 | "Background: Tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma has been limited by intensive lymphodepletion (high-dose cyclophosphamide/fludarabine) and high-dose IL-2, which cause significant toxicity. We explored GC101 TIL therapy using a low-intensity preconditioning regimen, cyclophosphamide 20 mg/kg/day from day -5 to day -3 and a single 600 mg oral hydroxychloroquine dose on day -5, along with IL-2-free TIL infusion, which showed encouraging outcomes in a prior phase I trial. This phase II study evaluates the optimized GC101 TIL therapy in melanoma patients refractory to PD-1 antibodies.Trial design: MIZAR-003 (NCT06703398) is a pivotal phase II, multicenter, randomized, open-label, parallel group, treatment study that will randomize 98 pts (1:1) to either Arm A: GC101 TIL therapy (study intervention includes tumor tissue resection>150mm3, preconditioning, 100mg sintilimab injection, TIL infusion, and thereafter, 4-dose 100mg..."

Clinical • Metastases • P2 data • Tumor-infiltrating lymphocyte • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor

Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study. (PubMed, Prenat Diagn) - "Increased rates of hydrops fetalis and the need for pacing at birth in the Dexamethasone only group suggest a possible positive effect of Hydroxychloroquine in utero, even if administered after the diagnosis of CHB. This study is limited by the small sample size and the inability to control for covariates. Further multicenter studies would help explore whether adjunctive treatment with Hydroxychloroquine improves outcomes, even when initiated after CHB diagnosis."

Journal

Novel Sequential Therapy with Obinutuzumab and Telitacicept in Severe Lupus Nephritis with Glucocorticoid-Induced Avascular Necrosis (AVN) of the Femoral Head: A Case Report. (PubMed, Am J Case Rep) - "CASE REPORT We report the case of a 22-year-old woman with biopsy-proven class V LN 6 years ago, initially managed with prednisone, tacrolimus, and hydroxychloroquine. CONCLUSIONS This is the first reported case of severe SLE treated with sequential therapy involving Obinutuzumab followed by telitacicept. The combination therapy of B-cell depletion plus BAFF/APRIL inhibition could be a promising and rational treatment approach for SLE patients, especially those with severe SLE, which warrants further clinical trials to validate the efficacy and safety of the therapeutic regimen."

Journal • Diabetes • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Systemic Lupus Erythematosus

Comparative risks of mortality, cardiovascular events, and dementia with methotrexate versus hydroxychloroquine in rheumatoid arthritis: a retrospective cohort study. (PubMed, Ann Med Surg (Lond)) - "However, the results must be interpreted with significant caution due to major limitations, including the potential for residual confounding from unmeasured variables like disease severity and the absence of adherence data. Further prospective research that addresses these limitations is warranted to confirm these associations and explore underlying mechanisms."

Journal • Retrospective data • Alzheimer's Disease • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Dementia • Hypertension • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Myocardial Infarction • Nephrology • Osteoporosis • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology